Bioventus appoints Ajay Dhankhar to board as Class II director

Bioventus Inc. (NASDAQ:BVS) announced the appointment of Ajay Dhankhar, PhD, to its board of directors as a Class II director, effective Thursday. Dr. Dhankhar will serve until the company’s 2026 annual meeting of stockholders or until a successor is selected and qualified.

According to the company’s statement in a press release and SEC filing, Dr. Dhankhar, 54, is currently the Chief Corporate Development & Strategy Officer at Smith & Nephew plc (NYSE:SNN), a role he has held since June 2025. Prior to joining Smith & Nephew, he founded Bluish Capital in July 2024, serving as its Managing Partner. Dr. Dhankhar also served as Managing Director in the Financial Advisory Healthcare Group of Lazard Ltd (NYSE:LAZ) from July 2022 to June 2024, where he was Global Head of Medical Technology, Diagnostics and Tools. Before that, he spent 25 years at McKinsey & Company in various leadership positions, including Senior Partner and Global Head of Strategy and M&A for Life Sciences.

Dr. Dhankhar holds a B.S. in Physics and Computer Science from Angelo State University and a PhD in Molecular Biophysics and Biochemistry from Yale University.

The company’s Stockholders Agreement allows Smith & Nephew, Inc. and its affiliates to designate up to two directors to the Bioventus board, provided they maintain a specified minimum shareholding. Dr. Dhankhar is the second designee of Smith & Nephew stockholders, joining current director Philip G. Cowdy.

Bioventus stated that Dr. Dhankhar will not receive compensation for his service as a director. The company also reported that Dr. Dhankhar has no family relationships with other directors or executive officers and no material interests in transactions requiring disclosure under SEC regulations.

This information is based on a press release statement and details provided in a recent SEC filing.

In other recent news, Bioventus Inc. reported its third-quarter 2025 earnings, surpassing expectations with an adjusted earnings per share (EPS) of $0.15, compared to the forecasted $0.11. This resulted in a 36.36% earnings surprise. The company’s revenue for the quarter reached $139 million, slightly exceeding the anticipated $137.65 million. Despite the positive earnings and revenue results, Bioventus experienced a premarket stock decline of 2.29%. Analyst firms have not yet issued any upgrades or downgrades following these results. These developments are part of the recent updates concerning Bioventus. Investors are keenly observing these figures as they assess the company’s financial performance. The earnings and revenue outcomes are crucial indicators for stakeholders evaluating Bioventus’ market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.